These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28162857)

  • 1. Design, synthesis and biological evaluation of 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives as anti-prostate cancer agents.
    Saravanan K; Elancheran R; Divakar S; Anand SA; Ramanathan M; Kotoky J; Lokanath NK; Kabilan S
    Bioorg Med Chem Lett; 2017 Mar; 27(5):1199-1204. PubMed ID: 28162857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis and Biological Evaluation of Novel 1, 3- thiazolidine-2, 4-diones as Anti-prostate Cancer Agents.
    Elancheran R; Saravanan K; Divakar S; Kumari S; Maruthanila VL; Kabilan S; Ramanathan M; Devi R; Kotoky J
    Anticancer Agents Med Chem; 2017; 17(13):1756-1768. PubMed ID: 28403781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, crystal structure and effect of indeno[1,2-b]indole derivatives on prostate cancer in vitro. Potential effect against MMP-9.
    Lobo G; Monasterios M; Rodrigues J; Gamboa N; Capparelli MV; Martínez-Cuevas J; Lein M; Jung K; Abramjuk C; Charris J
    Eur J Med Chem; 2015; 96():281-95. PubMed ID: 25899333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
    Kandil SB; Kariuki BM; McGuigan C; Westwell AD
    Bioorg Med Chem Lett; 2021 Mar; 36():127817. PubMed ID: 33513386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis and Biological Evaluation of 1-methyl-1H-pyrazole-5-Carboxamide Derivatives as Novel Anti-Prostate Cancer Agents.
    Chen X; Xu C; Li Y; Duan X; Zhao G
    Anticancer Agents Med Chem; 2021; 21(17):2368-2378. PubMed ID: 33530916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
    Ferla S; Bassetto M; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3636-40. PubMed ID: 27301368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
    Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
    Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and apoptosis inducing effect of novel (Z)-3-(3'-methoxy-4'-(2-amino-2-oxoethoxy)-benzylidene)indolin-2-ones as potential antitumour agents.
    Senwar KR; Reddy TS; Thummuri D; Sharma P; Naidu VG; Srinivasulu G; Shankaraiah N
    Eur J Med Chem; 2016 Aug; 118():34-46. PubMed ID: 27128173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
    Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of novel indole derivatives as promising DNA-binding agents and evaluation of antitumor and antitopoisomerase I activities.
    Lafayette EA; de Almeida SMV; Cavalcanti Santos RV; de Oliveira JF; Amorim CADC; da Silva RMF; Pitta MGDR; Pitta IDR; de Moura RO; de Carvalho Júnior LB; de Melo Rêgo MJB; de Lima MDCA
    Eur J Med Chem; 2017 Aug; 136():511-522. PubMed ID: 28531811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines.
    Chen H; Xu F; Liang X; Xu BB; Yang ZL; He XL; Huang BY; Yuan M
    Bioorg Med Chem Lett; 2015 Jan; 25(2):285-7. PubMed ID: 25488843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives.
    Ji XY; Xue ST; Zhan YC; Shen JJ; Wu LT; Jin J; Wang Z; Li ZR
    Eur J Med Chem; 2014 Aug; 83():409-18. PubMed ID: 24996136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analogue-based design, synthesis and biological evaluation of 3-substituted-(methylenehydrazono)indolin-2-ones as anticancer agents.
    Dweedar HE; Mahrous H; Ibrahim HS; Abdel-Aziz HA
    Eur J Med Chem; 2014 May; 78():275-80. PubMed ID: 24686014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
    Kandil S; Westwell AD; McGuigan C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, biological evaluation, and molecular docking studies of novel 1-benzene acyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as potential tubulin polymerization inhibitors.
    Wang YT; Qin YJ; Yang N; Zhang YL; Liu CH; Zhu HL
    Eur J Med Chem; 2015 Jun; 99():125-37. PubMed ID: 26070164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).
    Ban F; Leblanc E; Li H; Munuganti RS; Frewin K; Rennie PS; Cherkasov A
    J Med Chem; 2014 Aug; 57(15):6867-72. PubMed ID: 25025737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative, antiandrogenic and cytotoxic effects of novel caffeic acid derivatives in LNCaP human androgen-dependent prostate cancer cells.
    Sanderson JT; Clabault H; Patton C; Lassalle-Claux G; Jean-François J; Paré AF; Hébert MJ; Surette ME; Touaibia M
    Bioorg Med Chem; 2013 Nov; 21(22):7182-93. PubMed ID: 24080105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.